ESC Congress 2024
PACMAN-AMI: new data on lesion-level effects of lipid lowering
A new pre-specified, post-hoc analysis of results from the PACMAN-AMI study has shown that lesion-level effects of intensive lipid lowering with alirocumab and statin are substantially greater than those previously seen at vessel level.1 The new findings, presented by Dr Flavio Giuseppe Biccire (Inselspital, University…
read more »
AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS
Early, intensive lipid-lowering therapy including PCSK9 inhibition in patients with acute coronary syndrome (ACS) is associated with reduced risk of major adverse cardiovascular events (MACE), according to results from the AT-TARGET-IT registry using a ‘strike early, strike strong strategy’. In 771 patients with ACS who…
read more »
Real world ischaemic event reduction with PCSK9i mAbs
Initiation of PCSK9i mAbs in patients with atherosclerotic cardiovascular disease (ASCVD) but without prior ischaemic events is associated with significantly and substantially lower risk for major ischaemic events, concluded Professor Deepak Bhatt (Icahn School of Medicine at Mount Sinai, New York, USA) from results of…
read more »
Inclisiran role in plaque stabilisation
High intensity lipid lowering therapy, including inclisiran, has been shown to stabilise atherosclerotic plaques. In a study of 36 patients with stable coronary artery disease (CAD, 20-50% stenosis), atherosclerotic plaque lipid composition was evaluated before and after intensive lipid lowering therapy, using near-infrared spectroscopy (NIRS)….
read more »
Discontinuing PCSK9i leads to increased MACE
Patients who discontinue PCSK9i are at increased risk of major adverse cardiovascular events (MACE), suggests a study of 203 patients who received PCSK9i in Japan between July 2016 and December 2023. At one year, median LDL-C was 43 mg/dL, and 158 patients (77%) reached LDL-C…
read more »
